Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

US8853412B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Lothar Schwink · Stadtallendorf, DE
• Martin Bossart · Frankfurt am Main, DE
• Heiner Glombik · Hofheim, DE
• Matthias Gossel · Frankfurt am Main, DE
• Dieter Kadereit · Kelkheim, DE
• Thomas Klabunde · Frankfurt, DE
• Thomas Maier · Stockach, DE
• Siegfried Stengelin · Frankfurt am Main, DE

Key dates

• Filing date: Oct 8, 2013
• Grant date: Oct 7, 2014
• Expiry date: Oct 8, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.